THE 16th ANNUAL MEETING
JSGT2010
JAPAN SOCIETY OF GENE THERAPY

Program & Abstracts

Date
July 1-3, 2010

Venue
Tochigi-ken General Culture Center
1-8 Honcho, Utsunomiya city, 320-8530
Tochigi

JSGT Home-page URL: http://jsgt.jp
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50–11:00</td>
<td>Opening Remarks: President Keiya Ozawa</td>
</tr>
<tr>
<td>11:00–11:45</td>
<td>Plenary Session I (PL1–PL3) (E) Chairperson: Kenzaburo Tani</td>
</tr>
<tr>
<td>11:45–12:00</td>
<td>1st Takara Bio Award Lecture Takashi Okada (National Center of Neurology and Psychiatry) Chairperson: Yasufumi Kaneda</td>
</tr>
<tr>
<td>12:00–19:30</td>
<td>Poster Viewing (PO64–PO160)</td>
</tr>
<tr>
<td>12:05–12:50</td>
<td>Councilor’s Meeting</td>
</tr>
<tr>
<td>12:05–12:50</td>
<td>Corporate Seminar I Chairperson: Kazuto Takesako</td>
</tr>
<tr>
<td>12:05–12:50</td>
<td>Corporate Seminar II Chairperson: Yutaka Hanazono</td>
</tr>
<tr>
<td>12:05–12:50</td>
<td>Councilor’s Meeting</td>
</tr>
<tr>
<td>12:05–12:50</td>
<td>Corporate Seminar I Chairperson: Kazuto Takesako</td>
</tr>
<tr>
<td>12:05–12:50</td>
<td>Corporate Seminar II Chairperson: Yutaka Hanazono</td>
</tr>
<tr>
<td>12:55–13:35</td>
<td>General Assembly</td>
</tr>
<tr>
<td>13:40–14:05</td>
<td>Presidential Lecture Keiya Ozawa (Jichi Medical University) Chairperson: Shigetaka Asano</td>
</tr>
<tr>
<td>14:05–14:55</td>
<td>Special Lecture I (E) Chairperson: Keiya Ozawa</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>Educational Lecture I Hiroyuki Sasaki (Medical Institute of Bioregulation, Kyushu University) Chairperson: Yasufumi Kaneda</td>
</tr>
<tr>
<td>15:30–16:00</td>
<td>Educational Lecture II Hideyuki Okano (Keio University School of Medicine) Chairperson: Yoshiro Niitsu</td>
</tr>
<tr>
<td>15:00–16:00</td>
<td>Oral Session 1-Basic Science (OR8–OR13) Chairpersons: Kazunori Kato &amp; Takanori Yokota</td>
</tr>
<tr>
<td>16:00–16:15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:15–18:15</td>
<td>Main Symposium: “Recent Progress in Gene Therapy” (E) Chairpersons: Takashi Shimada &amp; Samuel Wadsworth</td>
</tr>
<tr>
<td>18:20–19:30</td>
<td>Poster Discussion (PO64–PO160)</td>
</tr>
<tr>
<td>18:45–20:00</td>
<td>Get-Together</td>
</tr>
</tbody>
</table>
Day II Friday, July 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chairpersons/Details</th>
</tr>
</thead>
</table>
| 09:00–10:00   | **Asian Session (E)** Chairpersons: Chae-Ok Yun & Masatoshi Tagawa                              | Sunyoung Kim (Seoul National University, Korea) “Enhanced angiogenesis by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA: Results from clinical trials for coronary and peripheral artery diseases”  
Yajun Guo (Second Military Medical University, China) “Novel monoclonal antibodies for cancer immunotherapy”  
Kam M. Hui (National Cancer Center, Singapore) “Targeting and eradicating human hepatocellular carcinoma cells in vivo with bone marrow-derived human mesenchymal stem cells transduced with oncolytic measles virus” |
| 09:00–09:30   | **Technical Seminar I** Chairperson: Mahito Nakanishi                                           | Makoto Otsu (The Institute of Medical Science, The University of Tokyo) “Application of emerging technologies to the gene and cellular therapy research: Introduction of an automated fluorescence microscopic imaging system” |
| 09:00–16:00   | **Poster Viewing (continue from Day 1: display alone)**                                        |                                                                                      |
| 09:30–10:00   | **Technical Seminar II** Chairperson: Yuii Heike                                               | Yukio Nakamura (RIKEN BioResource Center) “Cell Bank in Japan”                        |
| 10:05–11:05   | **Oral Session 4-Vector I: Molecular Aspects (OR26–OR31)** Chairpersons: Shuji Kubo & Osam Mazda |                                                                                      |
| 11:05–12:05   | **Oral Session 5-Vector II: Targeting (OR32–OR37)** Chairpersons: Ken-ichiro Kosai & Masashi Urabe |                                                                                      |
| 10:05–12:05   | **International Symposium (E)** Chairpersons: Noriyuki Kasahara & Hiroyuki Nakai                | Frank C. Marini (M.D. Anderson Cancer Center, USA) “Direct evidence for the use of modified mesenchymal stem/stromal cells as anticancer agents in animal models”  
Xiao Xiao (University of North Carolina, USA) “AAV-mediated regional and bodywide gene delivery of mini-dystrophin for DMD gene therapy in GRMD dog model”  
Chae-Ok Yun (Yonsei University College of Medicine, Korea) “Smart nanoconjugate; Opportunity for systemic administration of adenovirus for targeted cancer gene therapy”  
Glen N. Barber (University of Miami School of Medicine, USA) “Vesicular stomatitis virus as a viral therapeutic against cancer”  
Paul D. Robbins (University of Pittsburgh School of Medicine, USA) “Gene therapy for autoimmune diseases” |
Corporate Seminar IV Chairperson: Masafumi Takahashi  
Eiji Kobayashi (Jichi Medical University) “Bio-imaging animals-Preset and future application” |
| 13:00–13:50   | **Special Lecture II (E)** Chairperson: Hiroshi Shiku                                          | Richard A. Morgan (National Cancer Institute, National Institutes of Health, USA) “Recent progress and future directions using engineered T cells for the treatment of cancer” |
Tohru Minamino (Chiba University Graduate School of Medicine) “Another phase of therapeutic angiogenesis for cardiovascular disease”  
Yoshiaki Taniyama (Osaka University Graduate School of Medicine) “Hepatocyte growth factor protects senescence and function of endothelial precursor cell through PIP3/Akt inhibition”  
Ryosuke Uchibori (Jichi Medical University) “Mesenchymal stem cells as a cellular vehicle for cancer-targeted gene therapy”  
Shin Kaneko (The Institute of Medical Science, The University of Tokyo) “Leukemia immunotherapy with genetically modified T lymphocytes” |
| 15:45–16:00   | **Coffee Break**                                                                                |                                                                                      |
| 16:00–17:00   | **Plenary Session II (PL4–PL7)** Chairpersons: Izumu Saito & Yasutomo Nasu                     |                                                                                      |
| 17:10–18:35   | **Oya Stone Museum**                                                                            |                                                                                      |
| 18:45–20:30   | **Welcome Reception**                                                                           |                                                                                      |
**Day III Saturday, July 3**

09:00~10:30  **Joint Symposium with the Society of Immunotherapy for Hematological Malignancies (E)**

**Cancer Immunotherapy & Gene Therapy: “Genetically-engineered T-cell therapy for cancer”**

*Chairpersons: Masaki Yasukawa & Hiroaki Ikeda*

- **Masaki Yasukawa** (Ehime University Graduate School of Medicine)
  - "Introduction"

- **Hiroaki Ikeda** (Mie University Graduate School of Medicine)
  - "Gene-modified lymphocytes: A translational bridge to effective T cell therapy of cancer"

- **Hiroshi Fujiwara** (Ehime University Hospital)
  - "Development of a novel anti-leukemia immuno-gene therapy using WT1-specific T-cell receptor gene transfer"

- **Atsushi Natsume** (Nagoya University School of Medicine)
  - "Immunotherapy using retrovirally engineered T cells expressing chimeric antigen receptors specific to glioma-associated antigens"

- **Hiroyoshi Nishikawa** (Immunology Frontier Research Center, Osaka University)
  - "Role of regulatory T cells in anti-tumor immune responses"

09:00~09:30  **Technical Seminar III**

*Takashi Okada* (National Center of Neurology and Psychiatry)
- "Attractive features of AAV vector and methods for efficient production"

09:30~10:00  **Technical Seminar IV**

*Atsushi Tsuji* (National Institute of Radiological Sciences)
- "In vivo imaging with radiolabeled antibody"

10:05~11:05  **Oral Session 7-Cancer IV & Basic Technology (OR46~OR51) (E)**

*Chairpersons: Teruhiko Yoshida & Hiroyuki Miyoshi*

11:05~12:05  **Oral Session 8-Genetic, Neuromuscular & Other Diseases I (OR52~OR57) (E)**

*Chairpersons: Hiroaki Nunoi & Katsuto Tamai*

10:35~12:05  **Workshop 《Applications of Gene Transfer Technologies》**

1) **Hideki Katagiri** (Tohoku University Graduate School of Medicine)
   - "Metabolic harmony via neuronal information highways"

2) **Yutaka Hanazono** (Jichi Medical University)
   - "The generation and applications of iPSC cells with Sendai virus vectors"

3) **Takahiro Ochiya** (National Cancer Center Research Institute)
   - "Molecular therapy targeting cancer stem cells"

12:10~12:55  **Corporate Seminar V**

*Noboru Oriuchi* (University Graduate School of Medicine)
- "Application of 18F-FDG PET for cancer management"

**Corporate Seminar VI**

*Yutaka Kondo* (Aichi Cancer Center Research Institute)
- "Clinical implications of epigenetic treatment in human malignancies"

13:00~13:30  **Educational Lecture III**

*Tatsutoshi Nakahata* (Center for iPS Cell Research and Application (CiRA), Kyoto University)
- "Various clinical applications of induced pluripotent stem cells (iPS cells)"

13:30~14:00  **Educational Lecture IV**

*Tetsuo Noda* (The Cancer Institute of the Japanese Foundation for Cancer Research)
- "Hunting for molecular targets of cancer therapeutics using animal models of human carcinogenesis"

14:05~15:35  **Panel Discussion 《Future Prospects of Gene Therapy》**

*Chairpersons: Keiya Ozawa & Konosuke Mitani*

1) **Hematopoietic stem cell gene therapy: Masafumi Onodera** (National Center for Child Health and Development)
   - "A current situation of stem cell gene therapy"

2) **AAV vector Applications: Koichi Miyake** (Nippon Medical School)
   - "Application of AAV vectors for translational research"
   - "How can we deal with immune responses? Hiroaki Mizukami" (Jichi Medical University)
   - "Immune responses in AAV-mediated gene transfer"

3) **Cancer gene therapy: Noriyuki Kasahara** (University of California, Los Angeles, USA)
   - "Clinical gene therapy for cancer and leukemia: Progress and prospects"

15:35~15:45  **Closing Remarks:** President Keiya Ozawa & Welcome Greetings from the Next President: Kenzaburo Tani
PROGRAM
Presidential Lecture

Keiya Ozawa (Jichi Medical University)
Development of gene therapy: Current status and new directions

Date: July 1, 2010, 13:40-14:05, Sub-Hall
Chairperson: Shigetaka Asano

Special Lecture I (E)

Barrie J. Carter (ASGCT President; Carter BioConsulting, USA)
Clinical development of AAV vectors: Success in sight

Date: July 1, 2010, 14:05-14:55, Sub-Hall
Chairperson: Keiya Ozawa

Special Lecture II (E)

Richard A. Morgan (National Cancer Institute, National Institutes of Health, USA)
Recent progress and future directions using engineered T cells for the treatment of cancer

Date: July 2, 2010, 13:00-13:50, Sub-Hall
Chairperson: Hiroshi Shiku

Educational Lecture I

Hiroyuki Sasaki (Medical Institute of Bioregulation, Kyushu University)
Epigenetics in human disorder

Date: July 1, 2010, 15:00-15:30, Sub-Hall
Chairperson: Yasufumi Kaneda

Educational Lecture II

Hideyuki Okano (Keio University School of Medicine)
Strategies toward CNS-regeneration using iPS cell technology

Date: July 1, 2010, 15:30-16:00, Sub-Hall
Chairperson: Yoshiro Niitsu

Educational Lecture III

Tatsutoshi Nakahata (Center for iPS Cell Research and Application (CiRA), Kyoto University)
Various clinical applications of human induced pluripotent stem cells (iPS cells)

Date: July 3, 2010, 13:00-13:30, Sub-Hall
Chairperson: Yoshikatsu Eto

Educational Lecture IV

Tetsuo Noda (The Cancer Institute of the Japanese Foundation for Cancer Research)
Hunting for molecular targets of cancer therapeutics using animal models of human carcinogenesis

Date: July 3, 2010, 13:30-14:00, Sub-Hall
Chairperson: Jun Yoshida
Main Symposium (E)
“Recent Progress in Gene Therapy”
Date: July 1, 2010, 16:15-18:15, Sub-Hall
Chairpersons: Takashi Shimada & Samuel Wadsworth

Hiroyuki Nakai (University of Pittsburgh School of Medicine, USA)
Rapidly evolving adeno-associated viral vectors for gene therapy

Shin-ichi Muramatsu (Jichi Medical University)
AADC gene therapy for Parkinson’s disease: A phase I study

Shin’ichi Takeda (National Center of Neurology and Psychiatry)
Advances of molecular therapy research on dystrophin-deficient muscular dystrophy

Tomoki Todo (The University of Tokyo Hospital)
A clinical study of a third-generation oncolytic HSV-1 (G47Δ) in patients with recurrent glioblastoma

Toshiyoshi Fujiwara (Okayama University Graduate School)
Phase I clinical trial of telomerase-specific oncolytic adenovirus for human solid tumors

International Symposium (E)
Date: July 2, 2010, 10:05-12:05, Sub-Hall
Chairpersons: Noriyuki Kasahara & Hiroyuki Nakai

Frank C. Marini (M.D. Anderson Cancer Center, Houston, USA)
Direct evidence for the use of modified mesenchymal stem/stromal cells as anticancer agents in animal models

Xiao Xiao (The University of North Carolina, USA)
AAV-mediated regional and bodywide gene delivery of mini-dystrophin for DMD gene therapy in GRMD dog model

Chae-Ok Yun (Yonsei University College of Medicine, Korea)
Smart nanoconjugate; Opportunity for systemic administration of adenovirus for targeted cancer gene therapy

Glen N. Barber (University of Miami School of Medicine, USA)
Vesicular stomatitis virus as a viral therapeutic against cancer

Paul D. Robbins (University of Pittsburgh School of Medicine, USA)
Gene therapy for autoimmune diseases

Asian Session (E)
Date: July 2, 2010, 9:00-10:00, Sub-Hall
Chairpersons: Chae-Ok Yun & Masatoshi Tagawa

Sunyoung Kim (Seoul National University, Korea)
Enhanced angiogenesis by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA: Results from clinical trials for coronary and peripheral artery diseases

Yajun Guo (Second Military Medical University, China)
Novel monoclonal antibodies for cancer immunotherapy

Kam M. Hui (National Cancer Centre, Singapore)
Targeting and eradicating human hepatocellular carcinoma cells in vivo with bone marrow-derived human mesenchymal stem cells transduced with oncolytic measles virus
**Joint Symposium with the Japanese Vascular Biology and Medicine Organization (E)**

“New Frontier of Cell & Gene Therapy Toward Clinical Application”

Date: July 2, 2010, 13:55-15:45, Sub-Hall

Chairpersons: Ryuichi Morishita & Toshio Kitamura

Ryuichi Morishita (Osaka University Graduate School of Medicine)
Introduction: Progress of angiogenic gene therapy

Tohru Minamino (Chiba University Graduate School of Medicine)
Another phase of therapeutic angiogenesis for cardiovascular disease

Yoshiaki Taniyama (Osaka University Graduate School of Medicine)
Hepatocyte growth factor protects senescence and function of endothelial precursor cell through PIP3/Akt inhibition

Ryosuke Uchibori (Jichi Medical University)
Mesenchymal stem cells as a cellular vehicle for cancer-targeted gene therapy

Shin Kaneko (The Institute of Medical Science, The University of Tokyo)
Leukemia immunotherapy with genetically modified T lymphocytes

**Joint Symposium with the Society of Immunotherapy for Hematological Malignancies (E)**

“Genetically-Engineered T-Cell Therapy for Cancer”

Date: July 3, 2010, 9:00-10:30, Sub-Hall

Chairpersons: Masaki Yasukawa & Hiroaki Ikeda

Masaki Yasukawa (Ehime University Graduate School of Medicine)
Introduction

Hiroaki Ikeda (Mie University Graduate School of Medicine)
Gene-modified lymphocytes: A translational bridge to effective T cell therapy of cancer

Hiroshi Fujiwara (Ehime University Hospital)
Development of a novel anti-leukemia immuno-gene therapy using WT1-specific T-cell receptor gene transfer

Atsushi Natsume (Nagoya University School of Medicine)
Immunotherapy using retrovirally engineered T cells expressing chimeric antigen receptors specific to glioma-associated antigens

Hiroyoshi Nishikawa (Immunology Frontier Research Center, Osaka University)
Role of regulatory T cells in anti-tumor immune responses
Workshop
“Applications of Gene Transfer Technologies”
Date: July 3, 2010, 10:35-12:05, Sub-Hall
Chairperson: Toya Ohashi

Hideki Katagiri (Tohoku University Graduate School of Medicine)
Metabolic harmony via neuronal information highways

Chairperson: Fumio Endo

Yutaka Hanazono (Jichi Medical University)
The generation and applications of iPS cells with Sendai virus vectors

Chairperson: Hirofumi Hamada

Takahiro Ochiya (National Cancer Center Research Institute)
Molecular therapy targeting cancer stem cells

Panel Discussion
“Future Prospects of Gene Therapy”
Date: July 3, 2010, 14:05-15:35, Sub-Hall
Chairpersons: Keiya Ozawa & Konosuke Mitani

Masafumi Onodera (National Center for Child Health and Development)
A current situation of stem cell gene therapy

Koichi Miyake (Nippon Medical School)
Application of AAV vectors for translational research

Hiroaki Mizukami (Jichi Medical University)
Immune responses in AAV-mediated gene transfer

Noriyuki Kasahara (University of California, Los Angeles, USA)
Clinical gene therapy for cancer and leukemia: Progress and prospects

Clinical Trial Seminar (E)
“New Advance in Clinical Cancer Gene Therapy”
Date: July 2, 2010, 13:55-14:25, Special Room
Chairperson: Toshihiko Wakabayashi

Douglas J. Jolly (Tocagen Inc., USA)
Progress to the clinic of a novel prodrug activator gene transfer technology for the treatment of cancer
Technical Seminar I
Date: July 2, 2010, 9:00-9:30, Special Room
Chairperson: Mahito Nakanishi

Makoto Otsu (The Institute of Medical Science, The University of Tokyo)
Application of emerging technologies to the gene and cellular therapy research: Introduction of an automated fluorescense microscopic imaging system

Technical Seminar II
Date: July 2, 2010, 9:30-10:00, Special Room
Chairperson: Yuji Heike

Yukio Nakamura (RIKEN BioResource Center)
Cell Bank in Japan

Technical Seminar III
Date: July 3, 2010, 9:00-9:30, Special Room
Chairperson: Hiroyuki Mizuguchi

Takashi Okada (National Center of Neurology and Psychiatry)
Attractive features of AAV vectors and methods for efficient production

Technical Seminar IV
Date: July 3, 2010, 9:30-10:00, Special Room
Chairperson: Akihiro Kume

Atsushi Tsuji (National Institute of Radiological Sciences)
In vivo imaging with radiolabeled antibody

********************************************************************************

1st Takara Bio Award Lecture
Date: July 1, 2010, 11:45~12:00, Sub-Hall
Chairperson: Yasufumi Kaneda

Takashi Okada (National Center of Neurology and Psychiatry)
Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes
Plenary Session I (E) (Abstracts PL1~PL3)

Date: July 1, 2010, 11:00-11:45, Sub-Hall
Chairperson: Kenzaburo Tani

PL-1. Simple and efficient generation of foreign-gene-free human iPS cells without chromosomal damage using Sendai virus RNA vectors
Fusaki N., Ban H., Saeki K., Tabata T., Hasegawa M.

PL-2. Ex vivo expansion of human HSC with genotoxicity-free Sendai virus vector transiently expressing HoxB4 assessed by sheep in utero transplantation
Masuda S., Abe T., Ban H., Hayashi S., Takahashi H., Inoue M., Hasegawa M., Nagao Y., Hanazono Y.

PL-3. Inhibition of TGF-beta/activin signaling in the early phase or stimulation of activin signaling in the following phase combined with Wnt-3a stimulation enhances the differentiation into cardiac myocytes in mouse embryonic stem cells
Ueno S., Shimada S., Kario K.

Plenary Session II (E) (Abstracts PL4~PL7)

Date: July 2, 2010, 16:00-17:00, Sub-Hall
Chairpersons: Izumu Saito & Yasutomo Nasu

PL-4. Functional analysis of a novel gamma-secretase inhibitor, HIG1
Hayashi H., Nakagami H., Koibuchi N., Shimamura M., Kaneda Y.

PL-5. Gene therapy for aromatic L-amino acid decarboxylase deficiency
Hwu W-L., Muramatsu S., Wu R-M., Tseng S-H., Lee N-C., Snyder R. O., Chien Y-H.


PL-7. Autologous mononuclear cell implantation therapy for critical digit ischemia in patients with connective tissue diseases
Day 1: July 1, 2010

Oral Session 1 (Abstracts OR8–OR13)
Basic Science

15:00-16:00, Special Room
Chairpersons: Kazunori Kato & Takanori Yokota

OR-8. Generation of induced pluripotent stem cells from monkey and pig fibroblasts
Fujishiro S., Masuda S., Nishimura T., Fusaki N., Ueda Y., Hasegawa M., Takahashi K., Okita K., Yamanaka S., Hanazono Y.

OR-9. Characterization of iPS cells generated from murine hematopoietic cells

OR-10. Gene targeting in human pluripotent stem cells with adeno-associated virus vectors
Mitani K., Mitsui K., Suzuki K., Aizawa E., Kawase E., Suemori H., Nakatsuji N.

OR-11. Search for a key molecule of dendritic cell differentiation
Harada Y., Ueda Y., Yoshida K., Ichikawa T., Yonemitsu Y.

OR-12. Induction of type I interferon by virus-associated small RNAs
Yamaguchi T., Kawabata K., Konyama E., Suzuki T., Sakurai F., Kurachi S., Katayama K., Mizuguchi H.

OR-13. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

Oral Session 2 (Abstracts OR14–OR19)
Cancer I: Oncolytic Virotherapy

16:15-17:15, Special Room
Chairpersons: Akinobu Gotoh & Hideaki Shimada

OR-14. Efficient killing of glioma-initiating cells derived from human glioblastoma using the third generation oncolytic HSV-1 (G47Δ)
Takahashi M., Ino Y., Saito N., Todo T.

OR-15. Intrapleural inoculation with third generation oncolytic HSV-1 (G47Δ) is highly efficacious for experimental orthotopic malignant pleural mesothelioma
Takahashi M., Ino Y., Todo T.

OR-16. Enhancement of oncolytic virotherapy for malignant glioma: Concomitant administration of type I interferon binding protein

OR-17. Complete and sustained tumor regression of human malignant mesothelioma xenografts in athymic mice following local injection of midkine promoter-regulated oncolytic adenovirus
Kubo S., Kawasaki Y., Yamaoka N., Xu Y., Yamamoto H., Tagawa M., Kasahara N., Terada N., Okamura H.

OR-18. Development of a novel Coxsackievirus B oncolytic virotherapy against human lung cancer
Inoue H., Miyamoto S., Yamada M., Nakamura T., Urata Y., Shimizu H., Tani K.

OR-19. MicroRNA-regulated oncolytic vaccinia virus not only enhances the oncolytic activity but also reduces the viral pathogenicity
Nakamura T., Hikichi M., Kidokoro M., Shida H., Tahara H.
Oral Session 3 (Abstracts OR20~OR25)
Cancer II: Immunotherapy

17:15-18:15, Special Room
Chairpersons: Hiromi Kumon & Masato Abei

OR-20. Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus can suppress the growth of multiple lung tumors in mouse squamous cell carcinoma model

Ochi T., Fujiwara H., Nagai K., An J., Shirakata T., Mineno J., Kuzushima K., Yasukawa M.

OR-22. The next generation TCR gene therapy: Silencing of endogenous TCR improves the efficacy of TCR gene therapy
Okamoto S., Ikeda H., Fujiwara H., Yasukawa M., Shiku H., Mineno J.

OR-23. Immune responses in prostate cancer patients received in situ gene therapy of repeated HSV-tk injection and ganciclovir administration
Kubo M., Satoh T., Tabata K., Matsumoto K., Baba S., Obata F.

OR-24. Intratumoral delivery of interferon-alpha gene enhances tumor-specific immunity and suppresses immunological tolerance after autologous hematopoietic stem cell transplantation
Narumi K., Udagawa T., Kondoh A., Yoshida T., Aoki K.

OR-25. Augmented cancer immunotherapy by the use of STAT3-depleted dendritic cells
Sumimoto H., Iwata-Kajihara T., Mizuguchi H., Takeda K., Kawakami Y.

Day 2: July 2, 2010

Oral Session 4 (Abstracts OR26~OR31)
Vector I: Molecular Aspects

10:05-11:05, Special Room
Chairpersons: Shuji Kubo & Osam Mazda

OR-26. Molecular mechanisms of restricted growth of human adenovirus type 37 in A549 cells
Mitani K., Adachi K., Moroyama Y.

OR-27. Enhanced safety profiles of conditionally-replicating adenoviruses by insertion of target sequences to microRNA downregulated in tumor cells
Sakurai F., Sugio K., Katayama K., Matsu H., Kawabata K., Fujiwara T., Mizuguchi H.

OR-28. The chicken hypersensitive site-4 chromatin insulator sequence protects clonal dominance of hematopoietic stem cells transduced with a self-inactivating SIV vector in platelet-directed gene therapy
Ohmori T., Kashiwakura Y., Ishiwata A., Madoiwa S., Akiba E., Hasegawa M., Mimuro J., Ozawa K., Sakata Y.

OR-29. Optimization of lentiviral vector transduction into peripheral blood lymphocytes in combination with the fibronectin fragment CH-296 stimulation method
Chono H., Goto Y., Yamakawa S., Tanaka S., Tosaka Y., Nukaya I., Mineno J.

OR-30. Rendering CD4+ T lymphocytes resistant to HIV-1 replication via retroviral transduction of ACA-specific endoribonuclease MazF with Tat-dependent expression system
Tsuda H., Okamoto M., Chono H., Saito N., Inoue K., Baba M., Mineno J.

OR-31. Pre-clinical study for HIV-1 gene therapy using autologous transplantation of gene modified CD4+ T cells in primate models
Saito N., Tsuda H., Sakuraba T., Shibata H., Ageyama N., Chono H., Mineno J.
Oral Session 5 (Abstracts OR32~OR37)
Vector II: Targeting

11:05-12:05, Special Room
Chairpersons: Ken-ichiro Kosai & Masashi Urabe

OR-32. Efficient in vivo delivery of cholesterol-conjugated siRNA to the liver using endogenous chylomicron remnant
Yoshida K., Nishina K., Uno Y., Kuwahara H., Piao W., Mizusawa H., Yokota T.

OR-33. Histological analysis of in vivo liver-targeting pancreatic islet regeneration by helper-dependent adenovirus
Kojima H., Yechoor V., Terashima T., Chan L., Kimura H.

OR-34. Antibody-targeted selective gene and drug delivery for treatment of malignant melanoma
Hirai S., Yamaguchi M., Hamada H.

OR-35. Enhanced transduction efficiencies of fiber-substituted adenovirus vectors by incorporation of RGD peptide in two distinct regions of adenovirus serotype 35 fiber knob
Matsui H., Sakurai F., Katayama K., Kurachi S., Tashiro K., Sugio K., Kawabata K., Mizuguchi H.

OR-36. A SeV-F/HN-pseudotyped SIV vector enables long lasting expression in the murine lung, repetitive administration, and efficient transduction to human lung slice/airway models

OR-37. Highly efficient gene delivery system into the brain through retrograde axonal transport by using lentiviral vectors pseudotyped with rabies virus glycoprotein and its derivatives
Kobayashi K., Kato S., Kobayashi K., Inoue K., Takada M.

Oral Session 6 (Abstracts OR38~OR45)
Cancer III (E)

14:25-15:45, Special Room
Chairpersons: Hideaki Tahara & Masato Yamamoto

OR-38. Cancer immunotherapy with virus-specific T cells engineered to express HER2-specific chimeric antigen receptor using piggyBac transposons system
Nakazawa Y., Wilson M. H., Rooney C. M.

OR-39. Engineered T cells using both chemokine-receptor gene and tumor-specific TCR gene transfer for adoptive therapy
An J., Fujiwara H., Ochi T., Nagai K., Shirakata T., Mineno J., Kuzushima K., Yasukawa M.

OR-40. Intra-tumor secretion of GITRL-Fc fusion protein induces and activates tumor-specific CD8+ T cells resulting in tumor regression
Ikeda H., Mitsui J., Ishihara M., Hosoi H., Mineno J., Kondo S., Shiku H.

OR-41. Efficient induction of humoral and cellular immune responses against Her-2/neu by combination of naked DNA and adenoviral vectors expressing genetically engineered Her-2/neu

OR-42. Adenoviruses-mediated expression and cell-mediated delivery of interferon-lambda achieve anti-tumor effects in vivo
Tagawa M., Li Q., Kawamura K., Okamoto S., Yang S., Fujie H., Numazaki M., Shimada H., Kobayashi H.

OR-43. EpCAM- and EGFR- targeted selective gene therapy for biliary cancers using Z33-fiber modified adenovirus
Abe M., Kawashima R., Fukuda K., Nakamura K., Murata T., Yokoyama K. K., Hamada H., Hyodo I.
OR-44. Single injection of AAV-8 vector expressing mda-7/IL24 into muscle efficiently suppresses tumor growth in lymphoma model mice
Wang N., Fan B., Miyake K., Miyake N., Shimada T.

OR-45. Suicide gene modified central memory T lymphocyte infusion therapy against relapsed leukemia after allogeneic stem cell transplantation – An amended protocol of TK-DLI gene therapy

Day 3: July 3, 2010

Oral Session 7 (Abstracts OR46~OR51)
Cancer IV & Basic Technology (E)

10:05-11:05, Special Room
Chairpersons: Teruhiko Yoshida & Hiroyuki Miyoshi

OR-46. Novel therapeutic method using herpes oncolytic virus HF10 to treat advanced cancers

OR-47. Oncolytic adenovirus with a major late promoter-driven imagine cassette predicts in vivo anti-tumor effect

OR-48. Oncolytic adenovirus induces autophagic cell death through microRNA-7-mediated suppression of EGFR in human cancer cells
Tazawa H., Yano S., Yoshida R., Urata Y., Fujiwara T.

OR-49. Urokinase-targeted cell-cell fusion by oncolytic Sendai virus vector eradicates orthotropic glioblastomas by pronounced synergy with interferon-beta gene

OR-50. Human adenovirus type 40 vector engineering for intestinal mucosa targeting
Yamasaki S., Brown E., Davydova J., Vickers S. M., Yamamoto M.

OR-51. Transvascular transport of recombinant AAV9 vector is a capacity-limited caveolin-1-independent slow process that limits cardiac transduction

Oral Session 8 (Abstracts OR52~OR57)
Genetic, Neuromuscular & Other Diseases I (E)

11:05-12:05, Special Room
Chairpersons: Hiroyuki Nunoi & Katsuto Tamai

OR-52. Novel gene therapy for polyglutamine diseases to selectively degrade the pathogenic protein

OR-53. Parkin protects against parkinsonian insults induced by alpha-synuclein overexpression in a primate model
Yamazaki Y., Inoue K., Endo A., Nihira T., Yasuda T., Miyake K., Shimada T., Mizuno Y., Mochizuki H., Takada M.

OR-54. Positron emission tomography assessment of aromatic L-amino acid decarboxylase gene transfer in Parkinson's disease
OR-55. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice
Mimuro J., Ishiwata A., Mizukami H., Kashiwakura Y., Takano K., Ohmori T., Madoiwa S., Ozawa K., Sakata Y.

OR-56. Role of CXCR4 signaling in hematopoietic stem cell repopulation
Lai C. Y., Suzuki S., Okabe M., Yamazaki S., Otsu M., Nakauchi H.

OR-57. Lineage+/PDGFRα+/c-kit+ bone marrow cells are potential target of gene and cell therapy for genetic blistering skin disease, RDEB
Tamai K., Chino T., Yamazaki T., Inuma S., Kaneda Y.

Oral Session 9 (Abstracts OR58~OR63)
Genetic, Neuromuscular & Other Diseases II
13:00-14:00, Special Room
Chairpersons: Toshinao Kawai & Makoto Migita

OR-58. Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via lymphangiogenesis
Saito Y., Nakagami H., Morishita R., Azuma N., Sasajima T., Kaneda Y.

OR-59. Transdifferentiation of glioblastoma cells into vascular endothelial cells

OR-60. Successful factor IX expression by IV administration of AAV8 vectors in macaques

OR-61. Widespread transduction in the CNS and phenotypic correction of MLD model mice by systemic neonatal injection of serotype 9 AAV vector
Miyake N., Miyake K., Asakawa N., Okabe M., Yamamoto M., Shimada T.

OR-62. Lentiviral vector mediated delivery of full-length dystrophin for gene therapy of muscular dystrophy
Kimura E., Uchino K., Suga T., Koide T., Uchida Y., Maeda Y., Yamashita S., Chamberlain J., Uchino M.

OR-63. rAAV9-microdystrophin-mediated oral immunotolerance induction in canine X-linked muscular dystrophy
Hayashita-Kinoh H., Yugeta N., Okada H., Nitahara-Kasahara Y., Okada T., Takeda S.
Poster Session

Date: July 1, 2010, 18:20-19:30, 4th Gallery

(AbSTRACTS: PO64-PO94) Basic Science

PO-64. Tissue specific RNAi knockdown of DNA replication machinery in *Drosophila* showed requirement of replication factors in endoreplication, gene amplification and development
  Kohzaki H., Murakami Y.

PO-65. A flow cytometry-based method for screening of effective small interfering RNA target sequences

PO-66. The validation of siRNAs targeting mammalian target of rapamycin (mTOR) with cross-species activity to induce anti-tumoral effect
  Ahn J., Ko A., Jun E. J., Won M., Kim S. W., Lee H.

PO-67. A functional analysis of microRNA aberrantly expressed in leukemic cells
  Enomoto Y., Kitaura J., Sonoki T., Nakakuma H., Kitamura T.

PO-68. Identification of “oncogenic microRNA” as new therapeutic targets in malignant lymphoma
  Tagawa H., Yamanaka Y., Watanabe A., Inomata M., Sawada K.

PO-69. MicroRNA-222 is a potential target for developing blood-based biomarker assay and treatment of malignant glioma
  Ueda R., Qian L., Yaguchi T., Kosaka N., Fujita T., Okada H., Ochiya T., Kawakami Y.

PO-70. Development of new pMXs-based retrovirus vectors expressing shRNA
  Enomoto Y., Kitaura J., Nishimura K., Kitamura T.

PO-71. Silencing of a targeted protein in platelets using a lentiviral vector delivering short hairpin RNA sequence
  Ohmori T., Kashiwakura Y., Ishiwata A., Madoiwa S., Mimuro J., Sakata Y.

PO-72. c-Cbl regulates interaction of immature hematopoietic cells with the bone marrow microenvironment by Rac GTPase-mediated cytoskeletal signals
  Uehara E., Suzuki T., Okabe H., Ueda M., Nagai T., Sanada M., Ogawa S., Ozawa K.

PO-73. Differentiation of human mesenchymal stem cells: The potential mechanism for estrogen-induced preferential osteoblast vs. adipocyte differentiation
  Wan Y., Zhao Z., Gao Z., Mei H., Li Y.

PO-74. Mesenchymal stem cells inhibit Th17 differentiation through indoleamine-2,3-dioxygenase (IDO) and PGE2 production
  Tatara R., Ozaki K., Kikuchi Y., Hatanaka K., Oh I., Meguro A., Matsu H., Sato K., Nagai T., Muroi K., Ozawa K.

PO-75. The effect of DMXAA (5,6-di-methylxanthene-4-acetic acid) on MSC accumulation in tumor sites
  Uchibori R., Mizuguchi H., Tsukahara T., Urabe M., Mizukami H., Kume A., Ozawa K.

PO-76. *In vivo* comparison of the stemness ability among CD34+ cells derived from cord blood, bone marrow, peripheral blood using NOD/SCID x IL-2Rγnull (NOG) mice
  Horiuchi Y., Otsu M., Kiyokawa N., Fujimoto J., Onodera M.

PO-77. Glycine regulates the cell proliferation and differentiation of tissue stem cells and mouse embryonic stem cells
  Nakamura Y., Matsumoto S., Shiraki N., Mochida T., Nakamura K., Takehata K., Kume S., Endo F.

PO-78. Defining hypo-methylated region of stem cell-specific promoters despite general hyper-methylation status in human iPS cells
  Nishino K., Toyoda M., Yamazaki-Inoue M., Makino H., Fukawatase Y., Chikazawa E., Takahashi Y., Akutsu H., Umezawa A.
PO-79. Stem cell therapy for diabetes mellitus: Salivary gland derived progenitors
Matsumoto S., Okumura K., Hattori K., Iwai M., Nakamura K., Matsumoto M., Kaji Y., Nagashima H., Endo F.

PO-80. Cell processing of gene transducted T cells by RN/OKT3-stimulation method
Tanaka S., Nukaya I., Kobori H., Mineno J.

PO-81. Lymphocyte expansion from peripheral blood using recombinant human fibronectin fragment (CH-296; RetroNectin)

PO-82. Bio-luminescent imaging and characterization of organ-specific metastasis of human cancer in NOD/SCID mice
Murakami T., Chun N. A., Takahashi M.

PO-83. A third generation oncolytic HSV-1 armed with luciferase demonstrates persistent viral replication in tumors but not in normal organs
Wu Y., Ino Y., Todo T.

PO-84. False biological activities of hyaluronic acids are caused by impurities in the reagents
Sato K., Ozaki K., Matsu H., Tataria R., Meguro A., Oh I., Hatanaka K., Nagai T., Muroi K., Ozawa K.

PO-85. Growth inhibition by transduced hepcidin peptides in human embryonic kidney cells
Sasaki K., Ikuta K., Hosoki T., Ohtake T., Mizukami Y., Torimoto Y., Kohgo Y.

PO-86. Pro-proliferative functions of Drosophila small mitochondrial heat shock protein 22 in human cells

PO-87. Identification of novel minor histocompatibility antigens using HapMap EBV-LCL panels transduced with restricting HLA cDNA

PO-88. APOA-1 is a novel marker of erythroid cell maturation from hematopoietic stem cell

PO-89. Array-based genomic resequencing of acute myeloid leukemia
Yamashita Y., Mano H.

PO-90. Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma
Shimbo T., Tanemura A., Yamazaki T., Tamai K., Katayama I., Kaneda Y.

PO-91. Oxysterol binding protein like10 (OSBPL10) is associated with dyslipidemia
Nakagami H., Koriyama H., Katsuya T., Sugimoto K., Morishita R., Rakugi H., Kaneda Y.

PO-92. A quick and reliable method for titration of adenoviral vectors not using 293 cells
Kanegae Y., Pei Z., Terashima M., Kondo S., Saito I.

PO-93. Development of an enzyme-linked immunosorbent assay method for rapid screening of anti-AAV-2 antibodies
Ito T., Yamamoto S., Hayashi T., Kodera M., Mizukami H., Ozawa K., Nakano I., Muramatsu S.

PO-94. Prevalence of neutralizing antibodies against adeno-associated virus 2, 8 and 9 in non-human primate colonies using sensitive assay system
Yagi H., Mizukami H., Tsukahara T., Urabe M., Hamada H., Kume A., Yoshikawa H., Ozawa K.

(Abstracts: PO95~PO110) Vector

PO-95. Enhancement of adenoviral gene delivery and non-soluble drug delivery using proteoliposome containing apolipoproteins A-I
Cho K-H.
PO-96 Engineering DRG-targeted helper-dependent adenoviruses for selective gene delivery
Terashima T., Oka K., Kritz A. B., Kojima H., Yamakawa I., Kawai H., Sanada M., Baker A. H., Chan L.

PO-97 An adeno-associated virus vector efficiently and specifically transduce mouse skeletal muscle
Murakami I., Takeuchi T., Fujii T., Aoki D., Kanda T.

PO-98. TROP2-targeted selective gene therapy for non-small cell lung cancer (NSCLC)
Yamaguchi M., Hirai S., Hamada H.

PO-99. Evaluation of SSX4 gene promoter for tumor-specific suicide gene therapy
Yawata T., Ishida E., Shimizu K.

PO-100. Gene transduction into human hepatocytes transplanted into a chimeric mouse by using self-complementary recombinant AAV8 vectors
Ishida Y., Urabe M., Yamasaki C., Yanagi A., Yoshizane Y., Ozawa K., Tateno C.

PO-101. Editing cis elements required for AAV integration to enhance AAVS1-targeted integration
Urace M., Miyata S., Onishi A., Tsukahara T., Mizukami H., Kume A., Ozawa K.

PO-102. Prevention of teratogenesis in iPSC-based therapies with Nanog promoter driving HSV-TK / GCV mediated “pluripotent cell-suicide” system
Okimoto Y., Kaneko S., Yamaguchi T., Yamazaki S., Goto H., Inoue Y., Nakauchi H.

PO-103. “TET-OFF” lentiviral vectors drive high-level transgene expression in marmoset brains

PO-104. Expression of halorhodopsin for suppression of neuronal transmission in the central nervous system of the mouse and monkey with viral vectors

PO-105. Tracking of specific integrant clones in dogs treated with foamy virus vectors

PO-106. An erasable (hit-and-run) vector based on RNA replicon viruses may be useful in cell-programing/repograming without chromosomal damages
Ban H., Fusaki N., Iida A., Ueda Y., Inoue M., Hasegawa M.

PO-107. A novel method for gene transfer to mammalian cells by using Sendai virus-based minigenome system
You J., Inoue M., Tabata T., Shu T., Hasegawa M.

PO-108. Highly efficient gene transfer system using a laminin–DNA–apatite composite layer
Tsurushina H., Oyane A., Ito A., Matsumura A.

PO-109. Development of electromotor-driven system for hydrodynamic gene delivery

PO-110. Development of high-performance HVJ-E for cancer therapy
Saga K., Tamai K., Yamazaki T., Kaneda Y.

(Abstracts: PO111~PO138) Cancer

PO-111. Ex vivo expansion of primary T-lymphocytes expressing a chimeric antigen receptor targeting CD19 with antigen stimulation
Tsukahara T., Sakurai C., Ohmine K., Uchibori R., Urabe M., Mizukami H., Kume A., Riviere I., Sadelain M., Brentjens R. J., Ozawa K.

PO-112. Enhanced human T cell activity by silencing B7-H1 and B7-DC with siRNA
PO-113. A novel selective culture method of natural killer cells stimulated with alpha-galactosylceramide and Retronectin leads to the gene-transduction to NK cells
   Wakeda T., Yamaki Y., Kaida M., Hoshi Y., Takahashi N., Yamagata S., Shimada M., Takaue Y., Heike Y.

PO-114. Antigen mRNA-transfected, fibroblasts loaded with NKT cell ligand as adjuvant vector cells confer antitumor immunity
   Fujii S., Asakura M., Shimizu K.

PO-115. Establishment of aggressive MLL/AF4 induced lymphoma model mice through up-regulation of HoxA9 and S100A6 expression
   Tamai H., Miyake K., Takatori M., Miyake N., Yamaguchi H., Dan K., Shimada T., Inokuchi K.

PO-116. Transactivation of the dopamine receptor 3 gene by a single provirus integration results in development of B cell lymphoma in transgenic mice generated from retrovirally transduced embryonic stem cells
   Onodera M., Hirata Y., Hamaoka S.

PO-117. A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro
   Kawata E., Ashihara E., Hirai H., Maekawa T.

PO-118. Involvement of intercellular junctions mediated by E-cadherin in the resistance of ovarian mucinous carcinoma to anticancer drugs
   Saga Y., Mizukami H., Takei Y., Urabe M., Kume A., Suzuki M., Ozawa K.

PO-119. Galanin receptor type 1 suppresses proliferation in head and neck cancer cells

PO-120. RCAN1 interacts with an important role in the survival of leukemia cells

PO-121. Gene therapy for malignant mesothelioma using ‘BioKnife’, an urokinase-targeted oncolytic Sendai virus

PO-122. Combination of adenovirally delivered tumor necrosis factor-alpha with nafamostat mesilate is effective for pancreatic cancer by inhibiting NF-κB activation
   Furukawa K., Iida T., Fujisawa Y., Shiba H., Uwagawa T., Misawa T., Shimada Y., Kobayashi H., Ohashi T., Yanaga K.

PO-123. Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer

PO-124. E1B-55K-deleted oncolytic adenovirus CRAd-NTR(PS1217H6) caused mitotic catastrophe in colon cancer cells
   Chen M-J., Searle P. F., Chen Y-J.

PO-125. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy

PO-126. Adenovirus-mediated decorin expression induces cell death through activation of p53 and mitochondrial apoptosis
   Yoon A-R., Yun C-O.

PO-127. Combination therapy of conditionally replicating relaxin-expressing adenovirus with radiation effectively inhibits tumor growth
   Kim M., Kim J., Yoo J-Y., Kwon O-J., Yun C-O.

PO-128. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin targeting adeno-oncolytic virus

PO-129. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells co-expressing IL-12RB2 and IL-18Rα
   Choi I-K., Lee J-S., Zhang S-N., Yun C-O.
PO-130. Combined gene therapy using adenovirus expressing interleukin-12, granulocyte-macrophage colony-stimulating factor, and thymidine kinase with prodrug ganciclovir
Kim J.-S., Choi K.-J., Yun C.-O.

PO-131. Optimizing dendritic cell vaccination by combination with oncolytic adenovirus coexpressing interleukin-12 and granulocyte-macrophage colony stimulating factor

PO-132. Oncolytic virus therapy for bladder cancer using a third-generation HSV-1 armed with interleukin 12
Hou G., Fukuhara H., Tsurumaki Y., Homma Y., Ino Y., Todo T.

PO-133. A phase I/II study of adenovirus-mediated interleukin-12 gene therapy for hormone refractory prostate cancer: An interim report

PO-134. QOL score evaluation following IL-12 gene therapy for prostate cancer- An initial report of 2 cases
Onitake M., Kobayashi A., Ohta N., Munemiya M., Abarzua F., Nasu Y.

PO-135. Gene therapy clinics online: The direct-to-consumer business of gene therapy
Endo Y.

PO-136. Induction of long-term anti-tumoral effects via recombinant adeno-associated virus and its validation using micro-PET
Kim J. Y., Kim J. H., Lee W. I., Moon D. H., Lee H.

PO-137. Tumoricidal bystander effect in the suicide gene therapy using mesenchymal stem cells does not injure normal brain tissues
Namba H., Amano S., Koizumi S.

PO-138. Control of tumor-targeting Salmonella dissemination by host B-cell

(Abstracts: PO139~PO160) Genetic and Other Diseases

PO-139. Choice of small-sized promoter for AAV-mediated factor IX expression in skeletal muscle

PO-140. Neonatal gene therapy for the mouse model of Krabbe disease

PO-141. Long term gene expression in neonatal lentiviral gene therapy of MPS VII mice

PO-142. Chimerism of bone marrow reduces the glycolipid storage in Fabry disease mice

PO-143. AAV vector-mediated expression of interleukin-10 suppresses proteinuria in Zucker fatty rats through the improvement of glomerular hypertrophy and podocyte injury
Ogura M., Urabe M., Onishi A., Ito T., Tsukahara T., Mizukami H., Kume A., Kusano E., Ozawa K.

PO-144. Bone marrow mononuclear cell transplantation accelerates functional recovery after stroke in murine model
Hirose H., Kasahara Y., Myojin K., Nakano A., Saino O., Nakagomi T., Matsuyama T., Taguchi A.

PO-145. Critical role of hyaluronan derived from vascular smooth muscle cells in neointimal formation after vascular Injury
Kashima Y.

PO-146. Treatment of ischemic digits caused by connective tissue disease with local implantation of autologous bone marrow or peripheral blood mononuclear cells
Kamata Y., Iwamoto M., Muroi K., Minota S.
PO-147 5’ Tri-phosphate siRNA ; Attenuation of coxsackieviral myocarditis through gene silencing and RIG-I dependent interferon activation

PO-148. Long-term engraftment and survival of allogeneic transplanted multipotent mesenchymal stromal cells in Duchenne muscular dystrophy dog without immunosuppressant

PO-149. Feasibility study of adeno-associated virus (AAV) vector-mediated gene therapy for muscular dystrophy: Efficacy and safty of AAV serotype 2, 8, and in normal primate

PO-150. Hippocampal expression of GAD inhibits epileptogenesis in EL mice
Shimazaki K., Oguro K., Yokota H., Watanabe E., Kato K., Murashima Y., Kasahara Y., Okada T.

PO-151. AAV-OXTR vectors developed for the analysis of maternal behavior under the control of OXT/OXTR system
Osada D., Sato K., Aoyagi Y., Mizukami H., Ozawa K., Nishimori K.

PO-152. Parkin gene therapy in a long-term MPTP-minipump mouse model of Parkinson's disease; A second report
Yasuda T., Mochizuki H.

PO-153. Therapeutic vaccine in SIVmac239-infected rhesus macaque
Shimada M., Okuda K.

PO-154. AAV1-mediated IL-10 gene-delivery improves glucose and energy metabolism in high-fat diet-induced obese mice
Nakata M., Yamamoto S., Okada T., Ozawa K., Yada T.

PO-155. Altered effector CD4+ T cell function in IL-21R-/- CD4+ T cell-mediated graft-versus-host-disease

PO-156. Blocking of IL-21 signal attenuates graft-versus-host disease but not graft-versus-leukemia effect in a mouse model

PO-157. STAT3 activation is required for acute graft-versus host disease
Matsu H., Ozaki K., Meguro A., Hatanaka K., Tatara R., Oh I., Sato K., Mori M., Muroi K., Nagai T., Ozawa K.

PO-158. Transplanted allogeneic fetal membrane-derived mesenchymal stem cells contribute to renal repair in glomerulonephritis
Isaka Y., Tsuda H., Yamahara K., Ikeda T., Takabatake Y., Rakugi H.

PO-159. Mesenchymal stem cells stably transduced with a dominant negative inhibitor of MCP-1 greatly attenuated bleomycin-induced lung damage
Saito S., Nakayama T., Hashimoto N., Miyata Y., Egashira K., Yamamoto K., Hasegawa Y., Naoe T.

PO-160. Treatment with mesenchymal stem cells against steroid-resistant acute graft-versus-host disease after hematopoietic stem cell transplantation
Mori M., Muroi K., Sato K., Sasazaki M., Matsuyama T., Ozaki K., Ozawa K.
Corporate Seminars

Day I

Corporate Seminar-I (Takara Bio Inc.)

Thursday, JULY 1, 2010
12:05-12:50, Special Room

Chair: Kazuto Takesako (Gene Medicine Business Unit, Takara Bio Inc.)

Introduction of tools, technologies and applications for acceleration of your research and development of gene therapy
Junichi Mineno (Center for Cell and Gene Therapy, Takara Bio Inc.)

Corporate Seminar-II (DNAVEC Corporation)

Thursday, JULY 1, 2010
12:05-12:50, 1st Room

Chair: Yutaka Hanazono (Center for Molecular Medicine, Jichi University)

1. Efficient generation of IPS cells free from chromosomal damages and transgenes using an RNA replicon system, Sendai virus vector
Noemi Fusaki (PRESTO Research Leader, Unit of Cell Therapy & Regenerative Medicine, DNAVEC Corporation)

2. Development of DVC1-0101, a recombinant Sendai virus expressing human FGF-2, as a RNA drug to treat peripheral arterial disease
Yoshikazu Yonemitsu (R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University)

Day II

Corporate Seminar-III (Genzyme Japan K. K.) English presentation

Friday, JULY 2, 2010
12:10-12:55, Special Room

Chair: Tatsutoshi Nakahata (Center for iPS Cell Research and Application (CiRA), Institute for Integrated Cell-Material Sciences, Kyoto University)

Developing a gene therapy for the treatment of neovascular age-related macular degeneration
Samuel Wadsworth (Department of Molecular Biology, Genzyme Corporation, Framingham, MA, USA)

Corporate Seminar-IV (Otsuka Pharmaceutical Factory Inc.)

Friday, JULY 2, 2010
12:10-12:55, 1st Room

Chair: Masafumi Takahashi (Jichi Medical University)

Bio-imaging animals-Preset and future application
Eiji Kobayashi (Center for Development of Advanced Medical Technology, Jichi Medical University)

Day III

Corporate Seminar-V (Nihon Medi-Physics Co., Ltd.)

Saturday, JULY 3, 2010
12:10-12:55, Special Room

Chair: Hideharu Sugimoto (Jichi Medical University)

Application of 18F-FDG PET for cancer management
Noboru Oriuchi (Gunma University Graduate School of Medicine)

Corporate Seminar-VI (Nippon Shinyaku Co., Ltd.)

Saturday, JULY 3, 2010
12:10-12:55, 1st Room

Chair: Atsushi Natsume (Center for Genetic and Regenerative Medicine, Nagoya University School of Medicine)

Clinical implications of epigenetic treatment in human malignancies
Yutaka Kondo (Aichi Cancer Center Research Institute)